Evidence map›Paper›PMID 40502192›Full record

ArticlebioRxiv : the preprint server for biology2025

The striatal heterogeneous nuclear ribonucleoprotein H mRNA targetome associated with methamphetamine administration and behavior.

Qiu T Ruan, William B Lynch, Rebecca H Cole, Michael A Rieger, Britahny M Baskin, Sophia A Miracle, Jacob A Beierle, Emily J Yao, Jiayi W Cox, Amarpreet Kandola and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Qiu T RuanDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine; Boston, MA USA.
William B LynchLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Rebecca H ColeLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Michael A RiegerDepartment of Genetics, Department of Psychiatry, Washington University School of Medicine in St. Louis; St. Louis, MO USA.
Britahny M BaskinLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Sophia A MiracleLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Jacob A BeierleDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine; Boston, MA USA.ORCID 0000-0001-6517-7614
Emily J YaoLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Jiayi W CoxTransformative Training Program in Addiction Science, Boston University Chobanian and Avedisian School of Medicine, Graduate Program for Neuroscience, Boston University; Boston, MA USA.
Amarpreet KandolaLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Kayla T RichardsonLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Melanie M ChenLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Julia C KelliherLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
R Keith BabbsLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University; Boston, MA USA.
Peter E A AshLaboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University Chobanian and Avedisian School of Medicine; Boston, MA USA.
Benjamin WolozinLaboratory of Neurodegeneration, Department of Pharmacology and Experimental Therapeutics and Neurology, Boston University Chobanian and Avedisian School of Medicine; Boston, MA USA.
Karen K SzumlinskiDepartment of Psychological and Brain Sciences, University of California; Santa Barbara, CA USA.
W Evan JohnsonDivision of Infectious Disease, Department of Medicine and Center for Data Science, Rutgers University - New Jersey Medical School; Newark, NJ USA.
Joseph D DoughertyDepartment of Genetics, Department of Psychiatry, Washington University School of Medicine in St. Louis; St. Louis, MO USA.ORCID 0000-0002-6385-3997
Camron D BryantDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine; Boston, MA USA.

Funding

A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypesU01DA050243 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D · 2020 to 2023
$3.3M
Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in miceR01DA039168 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BRYANT, CAMRON D · 2015 to 2019
$3.0M
BU PREPR25GM125511 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HENDERSON, ANDREW J, SCHON, KARIN · 2020 to 2024
$1.4M
Training Program on Development of Medications for Substance Use DisorderT32DA055553 · NIDA · NORTHEASTERN UNIVERSITY · PI Raymond G. Booth, Alexandros Makriyannis · 2022 to 2026
$1.3M
The role of Zhx2 in CYP2D regulation, oxycodone metabolism, and opioid addiction model behaviors.F31DA056217 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LYNCH, WILLIAM · 2023 to 2024
$97k
NIDA NIH HHS F31 DA056217NIDA NIH HHS R01 DA039168NIDA NIH HHS T32 DA055553NIDA NIH HHS U01 DA050243NIGMS NIH HHS R25 GM125511
6 · The paper itself

Abstract

Methamphetamine addiction remains a major public health concern in the United States that has paralleled the opioid epidemic. Psychostimulant use disorders have a heritable genetic component that remains unexplained. Methamphetamine targets membrane and vesicular transporters to increase synaptic dopamine, norepinephrine, and serotonin. We previously identified

Indexed as

alternative splicingamphetaminecocainegabapentinlocomotionLyricapsychostimulant use disorder

Identifiers

PMID40502192
PMCPMC12154668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.